Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Sometimes equities that have been pushed too far down are at risk of surprisingly bouncing back.
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for...
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative...
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront...
Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated...